Clinical trial · Observational
Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in Patients With Stage II-IIIB Non-Small Cell Lung Cancer: A Single-Center, Real-World, Open-Label Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study intends to conduct a prospective, non-interventional study to compare the survival benefits of different surgical resection patterns for patients with non-small cell lung cancer who have achieved partial response (PR) after immunotherapy induction. The study plans to enroll patients suitable for surgery as assessed by radiomics evaluation and multidisciplinary team (MDT) discussion, and will assign them to the modified surgery group and the conventional surgery group based on patient preference. The resection scope in the modified surgery group is more limited compared to conventional surgery, aiming to maximize preservation of pulmonary function while ensuring oncological safety. This study will systematically evaluate the impact of different resection scopes on patient prognosis after neoadjuvant immunotherapy, providing clinical evidence for exploring individualized surgical strategies for non-small cell lung cancer in the era of immunotherapy.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Neoadjuvant Immunotherapy | — | UNRESOLVED | — |
| Surgery | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Conventional Surgery Group
- description
- Perform a pneumonectomy or composite lobectomy within the originally planned scope
- label
- Modified/Reduced Surgery Group
- description
- Under the premise of ensuring R0 resection, reduce the surgical scope, prefer composite lobectomy or lobectomy to maximize the preservation of pulmonary function.
Primary outcomes (1)
- measure
- Disease-free survival
- timeFrame
- Evaluate over a period of up to five years
- description
- It refers to the period from the beginning of the study until the recurrence of the disease or any cause of death.
Secondary outcomes (3)
- measure
- Overall Survival (OS)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed non-small cell lung cancer (NSCLC) * Achieved resectability after neoadjuvant immunotherapy with or without chemotherapy * Initially required pneumonectomy or combined lobectomy based on tumor size and extent, but became suitable for minimally invasive resection after neoadjuvant treatment * Age ≥ 18 years * ECOG performance status score of 0-1 * Complete imaging, pathological, and follow-up data available Exclusion Criteria: * Disease progression (PD) after neoadjuvant therapy * Still required pneumonectomy or combined lobectomy after neoadjuvant therapy, with no reduction in the planned surgical extent * Intraoperative findings indicating that R0 resection was not feasible * Severe cardiopulmonary dysfunction or other complications that made the patient unable to tolerate surgery
References
Publications (0)
Data not yet available